Cagrilintide in sport: appetite, evidence and limitations

Where interest in sport comes from

Cagrilintide is discussed in physique and weight-management settings because it influences satiety. That explains a proposed use; it does not establish an approved sporting purpose or a favourable benefit–risk balance for a healthy athlete. Appetite is also a signal relevant to fuelling demanding activity. Removing that signal can look convenient during a restricted diet while leaving the actual energy requirement unchanged. A meaningful sporting discussion therefore includes health, sustained training and function, rather than equating easier food restriction with better performance.

What makes the molecule different

Cagrilintide is a long-acting analogue of amylin, a hormone involved in satiety regulation. It is not interchangeable with a GLP-1 receptor agonist simply because both appear in weight-loss discussions. Its combination with semaglutide is studied as a distinct intervention. The composition, formulation and evidence for that combination must not be assigned to an unrelated mixed product or a cagrilintide-only vial. Receptor and hormone explanations are useful background, but they do not show that muscle is preferentially preserved or exercise capacity improves.

Named studies and what they actually tested

Lau and colleagues published a phase 2 trial in The Lancet in 2021 involving 706 adults with overweight or obesity. Over 26 weeks, cagrilintide produced greater weight reduction than placebo; gastrointestinal effects were prominent. The trial did not establish athletic performance benefits.

Garvey and colleagues' REDEFINE 1 trial in the New England Journal of Medicine in 2025 randomised 3,417 adults across combination, single-component and placebo groups over 68 weeks. Cagrilintide–semaglutide produced greater weight reduction than placebo. Its treatment arms help separate component effects, but the combination headline cannot be attributed entirely to cagrilintide. Enebo and colleagues' 2021 Lancet phase 1b study also concerned coadministration with semaglutide, making the same distinction necessary.

Potential advantages versus unsupported sporting claims

A medicine that improves weight management may be useful for an appropriately selected patient with excess adiposity. That clinical aim is different from a lean athlete seeking cosmetic definition. To establish a sporting advantage, research would need to measure relevant tasks, training tolerance and body-composition changes, including absolute lean tissue. A headline about percentage weight loss does not answer these questions. Nor does a claim that a drug affects satiety demonstrate better nutrient partitioning or selective preservation of contractile muscle.

Disadvantages and safety uncertainties

The clinical studies reported gastrointestinal adverse events, including nausea. Such effects may affect willingness or ability to eat, which can become important during training. A mismatch between intake and sporting demands is a plausible clinical concern, rather than a quantified finding in these trials. Long-term tolerability and safety in lean athletes cannot be inferred from obesity cohorts or from a small early-phase study. Combining different appetite-altering substances adds uncertainty rather than automatically balancing their effects. An unverified formulation creates an additional product-quality question.

How to interpret the evidence without turning it into a regimen

Start by identifying the intervention: cagrilintide alone, semaglutide alone or the studied combination. Then identify the population and endpoint. This prevents a genuine obesity-treatment finding from becoming an unsupported promise about muscle, recovery or competition preparation. Clinical eligibility, any current regulatory authorisation and sport-specific medication rules need separate checks at the point of care. The studies named here are evidence to discuss with a qualified clinician, not instructions for self-directed combinations or rapid weight manipulation.